Background: About 2% to 5% of all primary-care patients have a somatization disorder, and somatic symptoms are strongly associated with comorbid depression and anxiety disorders. Objective: The authors evaluated the validity of the 15-item Somatization module of the Patient Health Questionnaire (PHQ-15) among psychiatric outpatients. Method: The PHQ-15 was administered to patients with somatic complaints; it was compared with the Beck Depression Inventory (BDI) and the General Health Questionnaire-12 (GHQ-12). Fifty-seven Korean subjects completed the survey. Results: The PHQ-15 exhibited significant internal consistency, and test-retest reliability. Convergent validity with the BDI and GHQ-12 were positive. Conclusion: These results indicate that the Korean version of the PHQ-15 is appropriate for measuring the severity of somatic symptoms in a psychiatric outpatient setting.
Bibliographical noteFunding Information:
Dr. Han has received research support from a Korea Research Foundation Grant ( MOEHRD ; KRF-2007–013-E00033 ) and from the Research Foundation of Korea Neuropsychiatric Association (2004 Jisan Lee SeJong Cultural Psychiatry Fund). Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser, and is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from NIH, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer, and Specialty, Inc., Organon, Jazz Pharmaceuticals, and Pfizer. Dr. Masand is a consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer, Inc., Targacept Inc., and Wyeth Pharmaceuticals, and is on the speaker's bureau of Astra-Zeneca, Bristol Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., and Wyeth Pharmaceuticals; has received research support from AstraZeneca, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and Wyeth Pharmaceuticals.
ASJC Scopus subject areas
- Arts and Humanities (miscellaneous)
- Applied Psychology
- Psychiatry and Mental health